PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for ITP patients: switching drugs after failed treatment
Disease control Not yet recruitingThis study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, they will either get a higher dose of rhTPO or switch to a different drug called eltrombopag. The goal is to see whi…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Can a vitamin a drug boost platelets in Hard-to-Treat ITP?
Disease control Not yet recruitingThis study tests all-trans retinoic acid (ATRA), a form of vitamin A, in adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite steroid treatment. About 192 participants will receive either ATRA or a placebo for 24 weeks. The goal is to see if ATRA can s…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot could help kids with bleeding disorder avoid bruising
Disease control Not yet recruitingThis phase 3 trial tests QL0911, a weekly injection, in 60 children aged 1 to 17 with chronic immune thrombocytopenia (ITP) who have low platelet counts. The goal is to see if the drug can safely raise platelet levels to reduce bleeding risk. Participants receive either QL0911 or…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail aims to tame rare bleeding disorder
Disease control Not yet recruitingThis phase 2 study tests whether combining orelabrutinib (a targeted drug) with romiplostim (a platelet booster) can improve platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to standard treatments. About 28 participants will receive …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo aims to boost platelets in bleeding disorder
Disease control Not yet recruitingThis early-stage trial is testing three different daily doses of zanubrutinib (80, 160, or 240 mg) combined with high-dose dexamethasone in 60 adults newly diagnosed with immune thrombocytopenia (ITP). The goal is to find the safest and most effective dose that helps maintain pla…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill raises hopes for low platelet disorder
Disease control Not yet recruitingThis early-stage trial tests golidocitinib, an oral drug, in adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. The study has two parts: first, finding a safe dose, then comparing the drug against a placebo in a blinded fashion. T…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1, PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug combo aims to stop bleeding disorder in its tracks
Disease control Not yet recruitingThis study tests a three-step treatment for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants first get steroids and a platelet-boosting protein in the hospital, then switch to an oral drug (el…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
ITP showdown: daily pill vs IV infusion in major new trial
Disease control Not yet recruitingThis phase 3 trial will compare two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. About 220 adults who didn't respond to steroids will be randomly assigned to take avatrombopag (a daily pil…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Ostfold Hospital Trust • Aim: Disease control
Last updated Jun 26, 2026 14:30 UTC
-
Real-World study to track Eltrombopag's effectiveness in ITP patients
Knowledge-focused Not yet recruitingThis study looks at how eltrombopag is actually used and how well it works in patients with immune thrombocytopenia (ITP) who have already tried steroids. Researchers will collect data from healthcare providers in the US, UK, and Germany, focusing on platelet count improvements w…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gene clues could unlock better diagnosis for blood disorders
Knowledge-focused Not yet recruitingThis study looks at two genes (IL-1β and IL-33) in 300 adults with low platelet counts caused by either primary immune thrombocytopenia (ITP) or lupus (SLE). Researchers will measure gene activity from a blood sample to see if these genes can help tell the two conditions apart. T…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC